johnnycomelately9 Monday, 10/13/14 01:27:04 AM Re:

New Post Public Reply Private Reply Replies (3) Message Board
energy_wave
johnnycomelately9 Monday, 10/13/14 01:27:04 AM

Re: Rcranga post# 49878

Post # of 49894

I understand that reading comprehension is a skill. The date of expiration is listed for EVERY claim I listed. EVERYBODY has the right to look and see right in my last post. Not a SINGLE claim I listed is expired presently. NOT A SINGLE ONE.

You refer to the quarterly but try to understand that the quarterly says 9 mineral properties. Shadow Mountain is one; Shooting Star another; Highland another; Winsome another, etc! What I listed was the claim cell #'s to only plots/claim cells we have the rights to presently. I'm sorry to hear that SOME didn't understand that the 60 mineral claims at Shadow Mountain equal ONE mineral property/site. That we have 60 claims at Shadow Mountain right on top of rare Earth goodness as good as it gets. At least that's what the infer-read readings suggest... To the tune of billions in extractable rare earths.

YES it's easy to quote the quarterly or S-1 out of context, but the quarterly doesn't list every claim with the EXACT claim numbers like the S-1 did because it isn't required in the quarterly... YOU DO REALIZE THAT EVERY CLAIM I LISTED CAN BE CHECKED WITH THE MINISTRIE OF MINES AND ALL EXPIRATION DATES ARE UP TO DATE? THE CLAIM NUMBERS ARE POSTED FOR EVERYONE AND CAN BE VERIFIED... How can anyone try to deny the claim numbers I shared and say they're false? Again they are listed in the S-1 because that is the public offering and they had to provide Canwealth's assets to the public for the public offering. Do you want me to list other assets outside of thousands of acres of land? Ok then I will go on...

Some of the claims that weren't renewed are mineral property, Highland Gold 2, and 30 claim cells from Shadow Mountain that were environmentally in question. Hopefully it's now positioned prime for development. First let's get the IPO so Canwealth can start trading and get business going.

My opinion: ICBT is worth buying for it's potential and I believe it will past it's 52-week high over the next year. Other's can say what they think but ICBS/Canwealth owns every claim I listed and even more. They show them in pictures on this ihub page. Today I just listed their claim numbers so others can go find them. Like I said, disprove ONE claim I just listed in my last post, I'm waiting?

Truth: LIES have brought the truth into question and the stock at .0014 and climbing to .0003. However, just a little DD shows some are trying to sabotage Garth Mcintosh and his companies. Most of us know about Farhill's Capital but ICBT is building and looking for new investments according to their website; so I think they're just getting started and growing. SORRY if I ruin any plans of deceiving but I've got Garth's back! People can keep trying but you can't stop the truth... Meanwhile, I'll bring to light all lies and show what is real... So what is real you ask? ICBT and it's rising PPS! And yes, I believe Garth really has plans to see ICBT grow, I don't think he wants to scam and rob shareholders like falsely perpetrated, he is the largest shareholder:


Quote:Mr. McIntosh is the president, director and a principal shareholder of ICBS, Ltd.



So do you think he expects ICBS shareholders to receive value from Canwealth since they own 60% of the shares?

Quote:Mr. McIntosh will comply with the guidelines enumerated in Rule 3a4-1(a). Neither Mr. McIntosh, nor any affiliates will be purchasing shares in the offering.

Since there is no active trading market for these securities, we will sell at a stated fixed price until securities are quoted on the OTC.



We all now know they're waiting on their symbol for OTCBB. We also know that Canwealth and more importantly ICBS have more assets and value than current market cap. We're seriously undervalued right now. STRONG BUY IMO:

Quote:Mr. Garth McIntosh, our Chairman of the Board, Chief Executive Officer and President, is also a majority shareholder of ICBS Ltd., which is our largest shareholder. As of September 30, 2013 and December 31, 2012, we have taken loans from our shareholders of $67,672 and $80,474, respectively. No formal repayment terms or arrangements existed. The above loans are non-interest bearing and payable on demand.

ICBS Ltd. has given a loan to us and also transferred assets to us worth $46,644 (net of sale to ICBS Ltd. of $5,334 during the nine months ended September 30, 2013) as of September 30, 2013. As of September 30, 2013, we acquired intangible assets of $23,688 through loans from related parties.




Lastly FYI: ICBT is an awesome Buy because Garth has the most invested in ICBS/ICBT's success. HE WILL NOT RECEIVE ANY SHARES OF CANWEALTH FROM THE IPO. He is MAJORITY Sharholder of ICBT, so he wins if we win and I believe he's dotting the i's and crossing the t's so all of us pre-ipo investors WIN! I Hope I'm right, because I would really like to see this happen and be the first of many lucrative investments for ICBS. People always tell us about what's failed but they act like success can't come with continual hard work... That a loser can't become a winner. I hope our subsidy is trading soon because it has BIG WINNER written all over it's public offering:


Quote:Upon acceptance of a subscription for shares, our transfer agent will issue the shares to the purchasers. We may continue to offer shares for an indefinite period of time after commencement of this offering or until we have sold all of the shares offered in this prospectus. During the offering period, no subscriber will be entitled to any refund of any subscription.

We will sell the shares primarily through our President and Chief Executive Officer, Garth McIntosh, who may be considered an underwriter as that term is defined in Section 2(a) (11). Mr. McIntosh will not receive any commission in connection with the sale of shares, although we may reimburse him for expenses incurred in connection with the offer and sale of the shares. Mr. McIntosh intends to sell the shares being registered according to the following plan of distribution:


§
Shares will be offered to friends, family and other associates of Mr. McIntosh through personal contacts; there will be no direct mail or advertising associated with this offering; and


§
Shares will be offered to individuals who have expressed interest to Mr. McIntosh in regards to investing in a start-up venture.

Mr. McIntosh will be relying on, and complying with, Rule 3a4-1(a) of the Exchange Act as a “safe harbor” from registration as a broker-dealer in connection with the offer and sales of the shares. In order to rely on such “safe harbor” provisions provided by Rule 3a4-1(a), he must be in compliance with all of the following:


§
he must not be subject to a statutory disqualification;


§
he must not be compensated in connection with such selling participation by payment of commissions or other payments based either directly or indirectly on such transactions;


§
he must not be an associated person of a broker-dealer;


§
he must primarily perform, or is intended primarily to perform at the end of the offering, substantial duties for or on behalf of Canwealth otherwise than in connection with transactions in securities; and


§
he must perform substantial duties for Canwealth after the close of the offering not connected with transactions in securities, and not have been associated with a broker or dealer for the preceding 12 months, and not participate in selling an offering of securities for any issuer more than once every 12 months.

Mr. McIntosh will comply with the guidelines enumerated in Rule 3a4-1(a). Neither Mr. McIntosh, nor any affiliates will be purchasing shares in the offering.

Since there is no active trading market for these securities, we will sell at a stated fixed price until securities are quoted on the OTC.

You may purchase shares by completing and manually executing a subscription agreement and delivering it with your payment in full for all shares, which you wish to purchase, to our offices. Your subscription shall not become effective until accepted by us and approved by our counsel. Acceptance will be based upon confirmation that you have purchased the shares in a state providing for an exemption from registration. Our subscription process is as follows:


§
a prospectus, with subscription agreement, is delivered by Canwealth to each offeree;


32



§
the subscription is completed by the offeree, and submitted with check to Canwealth where the subscription and a copy of the check is reviewed by securities counsel;


§
each subscription is reviewed by counsel for Canwealth to confirm the subscribing party completed the form, and to confirm the state of acceptance;


§
once approved by counsel, the subscription is accepted by Mr. McIntosh, and the funds deposited into an account labeled: Canwealth Minerals Corporation, within four (4) days of acceptance;


§
subscriptions not accepted will be are returned with the check un-deposited within 24 hours of determination of non-acceptance.

Icbs Ltd (ICBT) Stock Research Links

ICBT Board Company Profile Buy Rating Time & Sales News Filings Financials
big-wave_surfing_01.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading